Back to top
more

NovoCure Limited (NVCR)

(Delayed Data from NSDQ)

$22.01 USD

22.01
1,483,612

-0.26 (-1.17%)

Updated May 31, 2024 04:00 PM ET

After-Market: $22.00 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVCR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

NovoCure Limited [NVCR]

Reports for Purchase

Showing records 21 - 40 ( 210 total )

Company: NovoCure Limited

Industry: Medical Services

Record: 21

08/28/2023

Company Report

Pages: 6

INNOVATE-3 Did Not Meet Its Primary Endpoint; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 22

08/01/2023

Industry Report

Pages: 19

The Wedbush Monthly Check-Up: August 2023

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 23

07/27/2023

Company Report

Pages: 7

NouveauCure in 2024?

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 24

07/27/2023

Company Report

Pages: 5

2Q23 Recap: INNOVATE-3 Top-Line in 3Q23 is the Next Significant Catalyst; Optune Sales Are Beginning to Recover

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 25

07/21/2023

Daily Note

Pages: 4

PANOVA-3 Gets the Go Ahead from DMC

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 26

06/07/2023

Company Report

Pages: 6

TTFields'' Role in the 2L NSCLC Treatment Paradigm Is Unclear; Lowering PT to $85

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 27

06/07/2023

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 28

06/07/2023

Daily Note

Pages: 14

Initial Takeaways for Day 5 of ASCO 2023; Roundup for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 29

06/06/2023

Company Report

Pages: 4

Initial Thoughts on LUNAR: OS Data Are Positive Though ICI Arm Has Low Prior ICI Exposure

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 5.00

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 30

06/06/2023

Company Report

Pages: 11

Upgrading to Neutral With the Moon Shot Off, Near-Term Catalysts Limited

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 31

05/04/2023

Company Report

Pages: 6

NVCR Approaches its LUNAR Landing

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 32

05/04/2023

Company Report

Pages: 6

1Q23 Take: Look Beyond the Short-Term Optune Revenue Headwinds; Reiterating Buy and Lowering PT to $115

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 33

02/23/2023

Company Report

Pages: 6

GBM Franchise Flat; We Need to See the Full Moon (LUNAR Data)

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 34

02/23/2023

Company Report

Pages: 6

2023 to be a Reset Year for Optune; We Believe Risk/Reward Going Into INNOVATE-3 Top-Line Data Looks Favorable

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 35

02/21/2023

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 36

01/12/2023

Company Report

Pages: 6

Preliminary Optune Revenues Indicate Short-Term Impacts

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 37

01/10/2023

Daily Note

Pages: 12

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 38

01/10/2023

Company Report

Pages: 6

With Another No Growth Year, NVCR Needs Confirmation from Full LUNAR Data

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 39

01/05/2023

Company Report

Pages: 6

Ringing in a LUNAR New Year; Increasing PT to $140

Provider: H.C. Wainwright & Co., Inc.

Analyst: BODNAR E

Price: 12.50

Research Provided by a Third Party

Company: NovoCure Limited

Industry: Medical Services

Record: 40

01/05/2023

Company Report

Pages: 6

LUNAR Waxes; We Wonder When It Wanes

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party